Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intra-Osseous Co-Transplant of UCB and hMSC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02181478
Recruitment Status : Recruiting
First Posted : July 4, 2014
Last Update Posted : May 27, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Marcos de Lima, Case Comprehensive Cancer Center

Brief Summary:
This clinical trial studies intra-osseous donor umbilical cord blood and mesenchymal stromal cell co-transplant in treating patients with hematologic malignancies. Giving low doses of chemotherapy and total-body irradiation before a co-transplant of donor umbilical cord blood and mesenchymal stromal cells into the bone (intra-osseous) helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil at the time of transplant may stop this from happening.

Condition or disease Intervention/treatment Phase
Acute Lymphoblastic Leukemia Acute Myelogenous Leukemia Myelodysplastic Syndromes Myelofibrosis Relapsed Non-Hodgkin Lymphoma Refractory Non-Hodgkin Lymphoma Hodgkin Lymphoma Refractory Hodgkin Lymphoma Relapsed Chronic Lymphocytic Leukemia Refractory Chronic Lymphocytic Leukemia Lymphoid Malignancies Chronic Myelogenous Leukemia Drug: cyclophosphamide Drug: fludarabine phosphate Radiation: total-body irradiation Drug: cyclosporine Drug: mycophenolate mofetil Procedure: umbilical cord blood transplantation Procedure: mesenchymal stem cell transplantation Early Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. To estimate the feasibility of combining intra-osseous umbilical cord blood (UCB) hematopoietic stem cells and human mesenchymal stromal cells (hMSC) following reduced intensity conditioning (RIC).

SECONDARY OBJECTIVES:

I. To estimate the time to engraftment of intra-osseous (IO) UCB transplant combined with hMSC following RIC.

II. To estimate the safety profile of IO UBC transplant combined with hMSC.

OUTLINE:

REDUCED INTENSITY CONDITIONING: Patients receive cyclophosphamide intravenously (IV) over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total body irradiation (TBI) on day -1.

GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive cyclosporine orally (PO) or IV over 2 hours every 12 hours on beginning on days -5 to 100 with taper beginning on day 100 and mycophenolate mofetil IV or PO twice daily (BID) on days -5 to 100.

TRANSPLANT: Patients undergo intra-osseous UCB and hMSC co-transplant on day 0.

After completion of study treatment, patients are followed up at days 28 and 100, and then at 6, 9, and 12 months.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intra-osseous Co-transplant of Cord Blood and Mesenchymal Stromal Cells: A Feasibility Study
Actual Study Start Date : July 22, 2015
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : May 2020


Arm Intervention/treatment
Experimental: Treatment (intra-osseous UCB with hMSC co-transplant)

REDUCED INTENSITY CONDITIONING (RIC):

Flu/Cy/TBI: Patients receive cyclophosphamide IV over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total-body irradiation on day -1.

Flu/Mel: Patients receive fludarabine daily on days -5 to -2, a single dose of melphalan on day -2, and ATG on day -3 and day-2.

GVHD PROPHYLAXIS: Patients receive cyclosporine PO or IV over 2 hours every 12 hours on beginning on days -5 to 100 with taper beginning on day 100 and mycophenolate mofetil IV or PO BID on days -5 to 100.

TRANSPLANT: Patients undergo a co-transplantation of an intra-osseous umbilical cord blood transplantation and a mesenchymal stem cell transplantation on day 0.

Drug: cyclophosphamide
All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6
Other Names:
  • CPM
  • CTX
  • Cytoxan
  • Endoxan
  • Endoxana

Drug: fludarabine phosphate
Given by IV during prep at 40mg/m2 for 5 days
Other Names:
  • 2-F-ara-AMP
  • Beneflur
  • Fludara

Radiation: total-body irradiation
Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1
Other Name: TBI

Drug: cyclosporine
Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100
Other Names:
  • ciclosporin
  • cyclosporin
  • cyclosporin A
  • CYSP
  • Sandimmune

Drug: mycophenolate mofetil
Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated.
Other Names:
  • Cellcept
  • MMF

Procedure: umbilical cord blood transplantation
Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant.
Other Names:
  • cord blood transplantation
  • transplantation, umbilical cord blood
  • UCB transplantation

Procedure: mesenchymal stem cell transplantation
The total dosage of hMSC will be 2x10^6cells/kg (+/-20%).
Other Name: hMSC transplantation




Primary Outcome Measures :
  1. Number of patients with BM cellularity failure: Measure of feasibility [ Time Frame: 42 days after transplant ]
    Primary graft failure is defined by <10% BM cellularity in bone marrow biopsies. Failure in more than 30% of patients will indicate unfeasibility of treatment

  2. Number of patients with ANC failure without evidence of disease: Measure of feasibility [ Time Frame: 42 days after transplant ]
    Primary graft failure is defined by <500 ANC cell/ul in bone marrow biopsies. Failure in more than 30% of patients will indicate unfeasibility of treatment

  3. Number of patients with hematopoietic recovery without evidence of donor umbilical cord blood engraftment: Measure of feasibility [ Time Frame: 42 days after transplant ]
    Primary graft failure is defined by hematopoietic recovery with <10% donor cell chimerism. Failure in more than 30% of patients will indicate unfeasibility of treatment

  4. Number of patients with hematopoietic recovery without evidence of donor umbilical cord blood engraftment: Measure of feasibility [ Time Frame: 100 days after transplant ]
    Primary graft failure is defined by hematopoietic recovery with <40% donor cell chimerism. Failure in more than 30% of patients will indicate unfeasibility of treatment


Secondary Outcome Measures :
  1. Incidence of toxicities assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to 12 months ]
    Descriptive statistics will be used.

  2. Rate of neutrophil recovery [ Time Frame: Up to 12 months ]
    The rate of neutrophil recovery and median time of recovery will be estimated using the methods of Kaplan and Meier.

  3. Rate of platelet recovery [ Time Frame: Up to 12 months ]
    The rate of platelet recovery and median time of recovery will be estimated using the methods of Kaplan and Meier.

  4. Median time of neutrophil recovery [ Time Frame: Up to 12 months ]
    The median time of neutrophil recovery will be estimated using the methods of Kaplan and Meier.

  5. Median time of platelet recovery [ Time Frame: Up to 12 months ]
    The median time of platelet recovery will be estimated using the methods of Kaplan and Meier.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have one of the following malignancies:

    • Acute myelogenous leukemia (AML): high-risk AML including:

      • Antecedent hematological disease (e.g., myelodysplasia [MDS])
      • Treatment-related leukemia
      • Complete remission (first complete remission [CR1]) with poor-risk cytogenetics or molecular markers (e.g. fms-related tyrosine kinase 3 [Flt 3] mutation, 11q23, del 5, del 7, complex cytogenetics)
      • Second complete remission (CR2) or third complete remission (CR3)
      • Induction failure or first relapse with either

        • ≤ 10% blasts in the marrow and/or
        • ≤ 5% blasts in the peripheral blood
    • Acute lymphoblastic leukemia (ALL)

      • High-risk CR1 including:
      • Poor-risk cytogenetics (e.g., Philadelphia chromosome t(9;22)or 11q23 rearrangements)
      • Presence of minimal disease by flow cytometry after 2 or more cycles of chemotherapy
      • No complete remission (CR) within 4 weeks of initial treatment
      • Induction failure
      • CR2 or CR3 with either:

        • ≤ 10% blasts in the marrow and/or
        • ≤ 5% blasts in the peripheral blood
    • Myelodysplastic syndromes (MDS), Intermediate-1 (INT-1), intermediate-2 (INT-2) or high Revised International Prognostic Scoring System (IPSS-R) score that has failed at least 1 first line therapy
    • Myelofibrosis (MF):

      • Intermediate-2 or high risk by Dynamic International Prognostic Scoring System (DIPSS)-plus
      • Monosomal karyotype
      • Presence of inv(3)/i(17q) abnormalities
      • Other unfavorable karyotype OR leukocytes ≥40 X 10^9/L AND
      • Circulating blasts ≤ 9%
    • Relapsed or refractory lymphoid malignancies (including non-Hodgkin lymphoma, Hodgkin lymphoma and chronic lymphocytic leukemia) meeting the following criteria:

      • Disease status: stable disease, partial remission or 2nd and 3rd complete remission
    • Chronic myelogenous leukemia (CML) in second chronic phase after accelerated or blast crisis; blast crisis defined as:

      • Blast count ≥ 20% in the peripheral blood or bone marrow
      • Large foci of blasts on bone marrow
      • Presence of extra-medullary blastic infiltrate (myeloid sarcoma or chloroma)
    • Recipients of prior autologous or allogeneic transplant are eligible, as long as at least 3 months have passed since the transplant, and the patient fulfills other eligibility criteria
    • Eastern Cooperative Oncology Group (ECOG) performance status ≤2
    • Candidates for reduced intensity conditioning regimens
    • Patients who do not have HLA-matched (defined as matched in HLA A, B, C, and DRB1) related or unrelated donors, those who elect to undergo UCB even if they have a MRD or MUD, or patients who require a UCB either for emergency indications such as primary graft failure.
    • Cord Blood Units available through NMDP with the following minimal criteria:

      • HLA Match: 4/6 or better match (HLA A, B, DRB1)
      • Cell dose: Minimum of 2.0x107TNC/kg pre thaw
    • Concurrent therapy for extramedullary leukemia or central nervous system (CNS) lymphoma: concurrent therapy or prophylaxis for testicular leukemia, CNS leukemia, and CNS lymphoma including standard intrathecal chemotherapy and/or radiation therapy will be allowed as clinically indicated; such treatment may continue until the planned course is completed; subjects must be in CNS remission at the time of protocol enrollment if there is a history of CNS involvement
    • Subjects must have a back-up umbilical cord on the registry in addition to the umbilical cord being used in this study
    • Subjects must have the ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients with inadequate Organ Function as defined by:

    • Creatinine clearance < 30 ml/min
    • Bilirubin ≥ 2 x institutional upper limit of normal
    • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) ≥ 2 x institutional upper limit of normal
    • Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≥ 2 x institutional upper limit of normal
    • Corrected diffusing capacity of the lung for carbon monoxide (DLCOcorr) < 40% normal
  • Left ventricular ejection fraction < 35%
  • Patients with uncontrolled inter-current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant or breastfeeding women are excluded from this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02181478


Contacts
Layout table for location contacts
Contact: Leland Metheny, MD 216-983-4946 Leland.Metheny@uhhospitals.org

Locations
Layout table for location information
United States, Ohio
Case Comprehensive Cancer Center Recruiting
Cleveland, Ohio, United States, 44106-5065
Contact: Leland Metheny, MD    216-983-4946    Leland.Metheny@uhhospitals.org   
Contact: Marcos de Lima, MD    216-286-6869    Marcos.deLima@uhhospitals.org   
Principal Investigator: Leland Metheny         
Sponsors and Collaborators
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Leland Metheny, MD Case Comprehensive Cancer Center

Layout table for additonal information
Responsible Party: Marcos de Lima, Principal Investigator, Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT02181478     History of Changes
Other Study ID Numbers: CASE1Z14
NCI-2014-01316 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
CASE1Z14 ( Other Identifier: Case Comprehensive Cancer Center )
P30CA043703 ( U.S. NIH Grant/Contract )
First Posted: July 4, 2014    Key Record Dates
Last Update Posted: May 27, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Marcos de Lima, Case Comprehensive Cancer Center:
Total Body Irradiation
Human Mesenchymal Stromal Cells
hMSC
Cyclophosphamide
Fludarabine
Dimethyl Sulfoxide
DMSO
Cyclosporine
Mycophenolate Mofetil
MMF
Granulocyte- Colony Stimulating Factor
G-CSF
GVHD
Cancer
feasibility
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Leukemia
Lymphoma, Non-Hodgkin
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Myeloid
Hodgkin Disease
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Bone Marrow Diseases
Hematologic Diseases
Leukemia, B-Cell
Myeloproliferative Disorders
Cyclosporine
Mycophenolic Acid
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Cyclosporins
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs